gsk glp 1 agonist Science's 2023 Breakthrough: GLP-1R Agonists GLP-1 Drug Savings: A Complete

Pratley, V

Jantrapirom S, Nimlamool W, Chattipakorn N, Chattipakorn S, Temviriyanukul P, Inthachat W, et al

Understanding the mechanisms that drive the efficacy of this combination will no doubt be aggressively pursued in the coming years, along with the continued emergence of additional combinatorial approaches, further expanding pharmacological options for a more personalized metabolic medicine of the future

This overlap highlights their promise as pharmacological analogues of exercise, and underscores the need for biomarker-driven, disease-specific trials to establish whether GLP-1RAs can deliver durable disease modification across the spectrum of neurodegenerative diseases

After removing 2,716 duplicate records, 3,825 studies underwent title and abstract screening